HER2-Low Breast Cancer—Current Knowledge and Future Directions DOI Creative Commons
Abeer M. Shaaban,

Tanvier Kaur,

Elena Provenzano

et al.

Medicina, Journal Year: 2025, Volume and Issue: 61(4), P. 644 - 644

Published: April 1, 2025

The concept of binary classification HER2 status has recently been challenged following the DESTINY-Breast trial data showing a clinically meaningful response to antibody–drug conjugates (ADCs) in invasive breast cancer expressing low levels HER2. HER2-low is defined as an immunohistochemistry (IHC) score 1+ and 2+ without gene amplification. While does not represent biological entity, it encompasses both hormone receptor-positive triple-negative cancer. Differences exist between this group HER2-null In review, we provide update on HER2-ultralow cancer, including background data, evolution expression, current clinical guidelines, quality issues, future directions.

Language: Английский

HER2-Low Breast Cancer—Current Knowledge and Future Directions DOI Creative Commons
Abeer M. Shaaban,

Tanvier Kaur,

Elena Provenzano

et al.

Medicina, Journal Year: 2025, Volume and Issue: 61(4), P. 644 - 644

Published: April 1, 2025

The concept of binary classification HER2 status has recently been challenged following the DESTINY-Breast trial data showing a clinically meaningful response to antibody–drug conjugates (ADCs) in invasive breast cancer expressing low levels HER2. HER2-low is defined as an immunohistochemistry (IHC) score 1+ and 2+ without gene amplification. While does not represent biological entity, it encompasses both hormone receptor-positive triple-negative cancer. Differences exist between this group HER2-null In review, we provide update on HER2-ultralow cancer, including background data, evolution expression, current clinical guidelines, quality issues, future directions.

Language: Английский

Citations

0